[Clinical signs of visceral leishmaniasis in adults: is the manner of presentation changing?].
Although the typical clinical signs and symptoms of visceral leishmaniasis (VL) are always the same, in the recent years the disease has emerged in new settings, for example in HIV infected individuals, in organ transplant recipients, in patients with chronic liver disease, in pregnancy. At the same time, VL has emerged as a model for exploring the host-parasite interplay for intracellular infections. The common feature of VL is that it is fatal without treatment. Liposomal Amphotericin B is the first line treatment in developed countries. Unfortunately, the high cost makes this treatment unaffordable for developing countries.
Centro di Riferimento Regionale per la Leishmaniosi Viscerale, Dipartimento di Malattie Infettive, Seconda Università di Napoli.
G B
GB
Gaeta
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000469:parasitology; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D005260:Female; D006801:Humans; D007891:Leishmania / Q000276:immunology / Q000302:isolation & purification; D007898:Leishmaniasis, Visceral / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology / Q000473:pathology; D008081:Liposomes; D008297:Male; D011183:Postoperative Complications / Q000175:diagnosis / Q000469:parasitology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000469:parasitology
D000913:Antibodies, Protozoan; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B